Trial Profile
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-arm Parallel-Group, 12-Month Study to Evaluate the Safety and Efficacy of ALS-L1023 Administered in Combination with Ranibizumab in Patients with Neovascular (wet) Age-Related Macular Degeneration (AMD) (McEye Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs ALS L1023 (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms McEye Study
- Sponsors AngioLab Inc
- 09 Aug 2022 Status changed from recruiting to completed.
- 11 Jan 2021 Planned End Date changed from 30 Jul 2021 to 31 Dec 2021.
- 11 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.